Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Financings In Brief

This article was originally published in The Gray Sheet

Executive Summary

Inovise Medical: Additional $12.5 in funding announced Feb. 12 brings total equity investment to $22 mil. Proceeds go toward final development, sales and marketing activities for the Cardiovise DEC system, used to diagnose heart disease. Product is expected to be available in the U.S. by year-end. Founded in 1997 by Hewlett Packard executives, the Inovise's proprietary digital electroacoustic cardiography technology combines electrical and sound information to diagnose abnormal heart conditions, including coronary artery disease, heart failure, acute coronary syndrome and left ventricular hypertrophy. New investors MDS Capital Corp. and TAT Capital Partners, Ltd. led the secondary financing round...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT016118

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel